{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:33Z","timestamp":1792782993938,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81630097"],"award-info":[{"award-number":["81630097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81773718"],"award-info":[{"award-number":["81773718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2016-I2M-3-011"],"award-info":[{"award-number":["2016-I2M-3-011"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Sciences Fundamental Research Funds for the Central Universities","award":["2018RC350002"],"award-info":[{"award-number":["2018RC350002"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Drug Innovation Major Project","award":["2018ZX09711001-003-005"],"award-info":[{"award-number":["2018ZX09711001-003-005"]}]},{"name":"Drug Innovation Major Project","award":["2018ZX09711001-008-005"],"award-info":[{"award-number":["2018ZX09711001-008-005"]}]},{"name":"Drug Innovation Major Project","award":["2018ZX09711001-003-020"],"award-info":[{"award-number":["2018ZX09711001-003-020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00262-020-02699-1","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T13:05:12Z","timestamp":1605531912000},"page":"1527-1540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review"],"prefix":"10.1007","volume":"70","author":[{"given":"Zhe","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-qi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-4549","authenticated-orcid":false,"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2699_CR1","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/s1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551. https:\/\/doi.org\/10.1016\/s1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"2699_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria J-C, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473\u2013486. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat Rev Clin Oncol"},{"key":"2699_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008\u20131019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"2699_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"2699_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye ES, Anderson MS, Kampe O (2018) Autoimmune polyendocrine syndromes. N Engl J Med 378:1132\u20131141. https:\/\/doi.org\/10.1056\/NEJMra1713301","journal-title":"N Engl J Med"},{"key":"2699_CR6","first-page":"212","volume":"21","author":"MB Schmidt","year":"1926","unstructured":"Schmidt MB (1926) Eine biglandulare Erkrankung (Nebennieren und Schilddruse bei Morbus Addisonni). Dtsch Pathol Ges 21:212\u2013221","journal-title":"Dtsch Pathol Ges"},{"key":"2699_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","volume":"3","author":"G Lanzolla","year":"2019","unstructured":"Lanzolla G, Coppelli A, Cosottini M, Del Prato S, Marcocci C, Lupi I (2019) Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome. J Endocr Soc 3:496\u2013503. https:\/\/doi.org\/10.1210\/js.2018-00366","journal-title":"J Endocr Soc"},{"key":"2699_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0713-y","author":"A Gunjur","year":"2019","unstructured":"Gunjur A, Klein O, Kee D, Cebon J (2019) Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0713-y","journal-title":"J Immunother Cancer"},{"key":"2699_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/ijciis.Ijciis_15_17","volume":"7","author":"S Kuru","year":"2017","unstructured":"Kuru S, Khan N, Shaaban H (2017) Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. Int J Crit Illn Inj Sci 7:177\u2013180. https:\/\/doi.org\/10.4103\/ijciis.Ijciis_15_17","journal-title":"Int J Crit Illn Inj Sci"},{"key":"2699_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","volume":"53","author":"SH Kong","year":"2016","unstructured":"Kong SH, Lee SY, Yang YS, Kim TM, Kwak SH (2016) Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes. Acta Diabetol 53:853\u2013856. https:\/\/doi.org\/10.1007\/s00592-016-0872-y","journal-title":"Acta Diabetol"},{"key":"2699_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000456540","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Masood A, Bari S, Yavuz S, Grosbach AB (2017) Autoimmune diabetes and thyroiditis complicating treatment with nivolumab. Case Rep Oncol 10:230\u2013234. https:\/\/doi.org\/10.1159\/000456540","journal-title":"Case Rep Oncol"},{"key":"2699_CR12","doi-asserted-by":"publisher","DOI":"10.17179\/excli2018-1357","author":"K Aziz","year":"2018","unstructured":"Aziz K, Shahbaz A, Umair M, Sachmechi I (2018) Avelumab inducing hypothyroidism and hypoadrenalism: a case report and review of literature. Excli J. https:\/\/doi.org\/10.17179\/excli2018-1357","journal-title":"Excli J"},{"key":"2699_CR13","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1656","author":"MA Humayun","year":"2016","unstructured":"Humayun MA, Poole R (2016) A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment. Hormones (Athens). https:\/\/doi.org\/10.14310\/horm.2002.1656","journal-title":"Hormones (Athens)"},{"key":"2699_CR14","doi-asserted-by":"publisher","DOI":"10.1530\/edm-18-0153","author":"OA Hakami","year":"2019","unstructured":"Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH (2019) A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/edm-18-0153","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2699_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","volume":"65","author":"E Hansen","year":"2016","unstructured":"Hansen E, Sahasrabudhe D, Sievert L (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother 65:765\u2013767. https:\/\/doi.org\/10.1007\/s00262-016-1835-4","journal-title":"Cancer Immunol Immunother"},{"key":"2699_CR16","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","author":"I Lupi","year":"2019","unstructured":"Lupi I, Brancatella A, Cosottini M, Viola N, Lanzolla G, Sgr\u00f2 D, Di Dalmazi G, Latrofa F, Caturegli P, Marcocci C (2019) Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-l1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-19-0102","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2699_CR17","doi-asserted-by":"publisher","DOI":"10.1530\/edm-19-0098","author":"S Patel","year":"2019","unstructured":"Patel S, Chin V, Greenfield JR (2019) Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/edm-19-0098","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2699_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","volume":"66","author":"S Okahata","year":"2019","unstructured":"Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Noso S, Ikegami H, Shiba T (2019) Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. Endocr J 66:295\u2013300. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0328","journal-title":"Endocr J"},{"key":"2699_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0196-z","author":"JR Lowe","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA (2016) Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-016-0196-z","journal-title":"J Immunother Cancer"},{"key":"2699_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11102-018-0880-8","volume":"21","author":"M Sum","year":"2018","unstructured":"Sum M, Garcia FV (2018) Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis. Pituitary 21:556\u2013557. https:\/\/doi.org\/10.1007\/s11102-018-0880-8","journal-title":"Pituitary"},{"key":"2699_CR21","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","volume":"12","author":"L Marchand","year":"2017","unstructured":"Marchand L, Paulus V, Fabien N, P\u00e9rol M, Thivolet C, Vouillarmet J, Saintigny P (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol 12:e182\u2013e184. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.021","journal-title":"J Thorac Oncol"},{"key":"2699_CR22","doi-asserted-by":"publisher","DOI":"10.1530\/edm-18-0111","author":"P Tzoulis","year":"2018","unstructured":"Tzoulis P, Corbett RW, Ponnampalam S, Baker E, Heaton D, Doulgeraki T, Stebbing J (2018) Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/edm-18-0111","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2699_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231236","author":"C Martins Machado","year":"2019","unstructured":"Martins Machado C, Almeida Santos L, Barroso A, Oliveira MJ (2019) Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2019-231236","journal-title":"BMJ Case Rep"},{"key":"2699_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.244.33","volume":"244","author":"K Sakurai","year":"2018","unstructured":"Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z (2018) Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab. Tohoku J Exp Med 244:33\u201340. https:\/\/doi.org\/10.1620\/tjem.244.33","journal-title":"Tohoku J Exp Med"},{"key":"2699_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/js.2017-00170","volume":"1","author":"AC Paepegaey","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, Lethielleux G, Clerc J, Bertherat J, Kramkimel N, Groussin L (2017) Polyendocrinopathy resulting from pembrolizumab in a patient with a Malignant Melanoma. J Endocr Soc 1:646\u2013649. https:\/\/doi.org\/10.1210\/js.2017-00170","journal-title":"J Endocr Soc"},{"key":"2699_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5001","author":"A Erra","year":"2019","unstructured":"Erra A, Pannu BS, Patel S, Qureshi F, Soliman M (2019) A rare case of ipilimumab-induced reversible hypophysitis and permanent primary hypothyroidism. Cureus. https:\/\/doi.org\/10.7759\/cureus.5001","journal-title":"Cureus"},{"key":"2699_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13212","author":"S Kurihara","year":"2020","unstructured":"Kurihara S, Oikawa Y, Nakajima R, Satomura A, Tanaka R, Kagamu H, Shimada A (2020) Simultaneous development of graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: a case report. J Diabetes Investig. https:\/\/doi.org\/10.1111\/jdi.13212","journal-title":"J Diabetes Investig"},{"key":"2699_CR28","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0045","author":"JL Meng\u00edbar","year":"2019","unstructured":"Meng\u00edbar JL, Capel I, Bonfill T, Mazarico I, Espu\u00f1a LC, Caix\u00e0s A, Rigla M (2019) Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-19-0045","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2699_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265\u2013276. https:\/\/doi.org\/10.1016\/j.it.2015.02.008","journal-title":"Trends Immunol"},{"key":"2699_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"2699_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"2699_CR32","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer N (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"2699_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"2699_CR34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"2699_CR35","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092\u20132099. https:\/\/doi.org\/10.1200\/JCO.2014.60.0379","journal-title":"J Clin Oncol"},{"key":"2699_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. https:\/\/doi.org\/10.1136\/bmj.k4226","journal-title":"BMJ"},{"key":"2699_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 14:569\u2013579. https:\/\/doi.org\/10.1038\/s41584-018-0074-9","journal-title":"Nat Rev Rheumatol"},{"key":"2699_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"L-S Chang","year":"2019","unstructured":"Chang L-S, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"2699_CR39","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 13:1930\u20131939. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2035","journal-title":"J Thorac Oncol"},{"key":"2699_CR40","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16:626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90","journal-title":"Nat Rev Immunol"},{"key":"2699_CR41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 19:737\u2013746. https:\/\/doi.org\/10.1016\/s1470-2045(18)30261-4","journal-title":"Lancet Oncol"},{"key":"2699_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152:271\u2013281. https:\/\/doi.org\/10.1016\/j.chest.2017.04.177","journal-title":"Chest"},{"key":"2699_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2019","unstructured":"Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J (2019) Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol 6:375\u2013384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5367","journal-title":"JAMA Oncol"},{"key":"2699_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.gendis.2016.10.002","volume":"3","author":"L Min","year":"2016","unstructured":"Min L (2016) Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes Dis 3:252\u2013256. https:\/\/doi.org\/10.1016\/j.gendis.2016.10.002","journal-title":"Genes Dis"},{"key":"2699_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (2019) A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51:145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"key":"2699_CR46","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"2699_CR47","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402x.2017.1375642","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7:e1375642. https:\/\/doi.org\/10.1080\/2162402x.2017.1375642","journal-title":"Oncoimmunology"},{"key":"2699_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner F, Bomze D, Diem S, Ali OH, F\u00e4ssler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, L\u00e4ubli H, Zippelius A, Hartmann F, Cheng HW, H\u00f6nger G, Recher M, Goldman J, Cozzio A, Fr\u00fch M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L (2019) Association of Checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 5:1043\u20131047. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0402","journal-title":"JAMA Oncol"},{"key":"2699_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0779-6","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0779-6","journal-title":"J Immunother Cancer"},{"key":"2699_CR50","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.Ccr-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681\u20136688. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0187","journal-title":"Clin Cancer Res"},{"key":"2699_CR51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/jco.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792. https:\/\/doi.org\/10.1200\/jco.2015.66.1389","journal-title":"J Clin Oncol"},{"key":"2699_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-116","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandal\u00e0 M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P (2014) Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. https:\/\/doi.org\/10.1186\/1479-5876-12-116","journal-title":"J Transl Med"},{"key":"2699_CR53","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/jco.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043\u20136053. https:\/\/doi.org\/10.1200\/jco.2005.06.205","journal-title":"J Clin Oncol"},{"key":"2699_CR54","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Sch\u00e4ffer AA, Gr\u00fcning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LSK, Sansom DM, Grimbacher B (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20:1410\u20131416. https:\/\/doi.org\/10.1038\/nm.3746","journal-title":"Nat Med"},{"key":"2699_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000089293","volume":"64","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T, Iwasaki Y, Kumon Y, Suehiro T, Tanimoto N, Mizobuchi M, Nakamura T (2005) Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res 64:253\u2013260. https:\/\/doi.org\/10.1159\/000089293","journal-title":"Horm Res"},{"key":"2699_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/bf02342437","volume":"35","author":"T Awata","year":"1992","unstructured":"Awata T, Kuzuya T, Matsuda A, Iwamoto Y, Kanazawa Y (1992) Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 35:419\u2013424. https:\/\/doi.org\/10.1007\/bf02342437","journal-title":"Diabetologia"},{"key":"2699_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1399-0039.1996.tb02512.x","volume":"47","author":"S Yasunaga","year":"1996","unstructured":"Yasunaga S, Kimura A, Hamaguchi K, Ronningen KS, Sasazuki T (1996) Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 47:37\u201348. https:\/\/doi.org\/10.1111\/j.1399-0039.1996.tb02512.x","journal-title":"Tissue Antigens"},{"key":"2699_CR58","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","volume":"57","author":"H Erlich","year":"2008","unstructured":"Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P, Type 1 Diabetes Genetics C (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57:1084\u20131092. https:\/\/doi.org\/10.2337\/db07-1331","journal-title":"Diabetes"},{"key":"2699_CR59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/347151a0","volume":"347","author":"S Baekkeskov","year":"1990","unstructured":"Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151\u2013156. https:\/\/doi.org\/10.1038\/347151a0","journal-title":"Nature"},{"key":"2699_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-5793(85)80446-4","volume":"190","author":"B Czarnocka","year":"1985","unstructured":"Czarnocka B, Ruf J, Ferrand M, Carayon P, Lissitzky S (1985) Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Lett 190:147\u2013152. https:\/\/doi.org\/10.1016\/0014-5793(85)80446-4","journal-title":"FEBS Lett"},{"key":"2699_CR61","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/0140-6736(92)91829-w","volume":"339","author":"O Winqvist","year":"1992","unstructured":"Winqvist O, Karlsson FA, K\u00e4mpe O (1992) 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339:1559\u20131562. https:\/\/doi.org\/10.1016\/0140-6736(92)91829-w","journal-title":"Lancet"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02699-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T11:03:14Z","timestamp":1621681394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02699-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02699-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}